Overview

A Study of LY3451838 in Participants With Migraine

Status:
Recruiting
Trial end date:
2021-11-17
Target enrollment:
Participant gender:
Summary
The reason for this study is to see if the study drug LY3451838 is safe and effective in participants who have migraine that have not responded to other preventive treatments.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company